← All trials
NCT04690322
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- Dec 30, 2020
- Last posted
- Apr 23, 2021
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The University of Texas, DallasLead sponsor
- The University of Texas, DallasSponsor investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.